The Effects of Blood Pressure Reduction on Cerebral Perfusion and Cognition in the Elderly Population

NCT ID: NCT00966199

Last Updated: 2009-08-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-09-30

Study Completion Date

2013-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine if a reduction in systolic blood pressure induced by anti-hypertensive medication results in changes in cerebral perfusion and cognition in hypertensive elderly. Hypertensive elderly will be treated using open-label anti-hypertensive medication for 8-12 weeks. Changes in cerebral perfusion and cognition will be assessed before and after treatment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hypertensive elderly

community dwelling hypertensive elderly from general practices

Group Type EXPERIMENTAL

anti-hypertensive medication

Intervention Type DRUG

8-12 weeks of anti-hypertensive treatment with 2 weekly titration using registered hypertensive medication

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

anti-hypertensive medication

8-12 weeks of anti-hypertensive treatment with 2 weekly titration using registered hypertensive medication

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \>= 70 years
* Systolic office blood pressure \>= 160 mmHg
* Systolic home blood pressure \>= 155 mmHg

Exclusion Criteria

* Diabetes Mellitus
* Atrial fibrillation
* Dementia
* Renal failure requiring dialysis
* Life expectancy of less than 1 year
* Disabling stroke
* Contraindication for MRI or anti-hypertensive medication
* Systolic blood pressure \> 220 mmHg
Minimum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Dutch Heart Foundation

OTHER

Sponsor Role collaborator

Radboud University Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Radboud University Nijmegen Medical Centre

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jurgen A Claassen, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Radboud University Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Radboud University

Nijmegen, Gelderland, Netherlands

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Netherlands

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jaap C Sijbesma, MD

Role: CONTACT

0243616772 ext. +31

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jaap C Sijbesma, MD

Role: primary

0243616772 ext. +31

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2008B113

Identifier Type: -

Identifier Source: secondary_id

MBRACE

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Default BP Medication Intensification
NCT01994408 TERMINATED PHASE1/PHASE2
Angiotensin-(1-7) Cardiovascular Effects in Aging
NCT05301192 RECRUITING EARLY_PHASE1
The TARGET BP OFF-MED Trial
NCT03503773 COMPLETED PHASE2